CEO Bill Anderson tells Scrip that the switching of patients to the higher dose formulation of the eye disease drug will help secure its future as a big earner for Bayer.

Ebglyss sales, all from Germany, were €3.6m in the first quarter and while that may appear a little underwhelming at first glance, the Spanish drugmaker is impressed with the launch and its impact on dermatologists and patients.

The US biotech’s DB-OTO has made headlines worldwide after a baby with profound genetic deafness experienced improved hearing to normal levels within 24 weeks after a single intracochlear injection.

The voluntary withdrawal of the license for the UK major's COVID-19 vaccine is due to a surplus of available updated jabs from other companies that target new variants and is not connected to the mis- and disinformation being peddled on the internet and elsewhere on very rare adverse events.

The Sweden-headquartered biotech has emphasized the promising survival data in a head and neck cancer study of setanaxib rather than the NOX inhibitor’s inability to shrink tumors.

The two heavyweights have joined forces with fellow major charitable foundation Wellcome and committed $300m to "accelerate global health equity and impact."